DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Use of Fenofibrate for Primary Biliary Cirrhosis

Information source: University of Florida
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Primary Biliary Cirrhosis

Intervention: Fenofibrate (Insoluble Drug Delivery-Micro Particle Fenofibrate (IDD-P) (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: University of Florida

Official(s) and/or principal investigator(s):
Cynthia Levy, MD, Principal Investigator, Affiliation: University of Florida

Summary

This is a pilot study to evaluate the safety and efficacy of fenofibrate on patients with primary biliary cirrhosis who have an incomplete response to ursodeoxycholic acid.

Clinical Details

Official title: Pilot Study of Fenofibrate for Primary Biliary Cirrhosis

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Serum Level of Alkaline Phosphatase

Secondary outcome: Quality of Life According to NIDDK Questionnaire

Detailed description: This is a multicenter open label pilot study to evaluate the efficacy of fenofibrate in 20 patients with PBC treated for 1 year. A randomized design would not be feasible at this stage of the research. Two sites are enrolling patients: University of Florida, Gainesville, and Mayo Clinic Rochester, with the first as the coordinating site. The total number of patients to start treatment will not exceed 20. Our endpoints are 1) surrogate markers of

disease activity - serum alkaline phosphatase and immunoglobulin M; 2) a well validated

prognostic index - Mayo risk score and 3) the NIDDK quality of life questionnaire.

Eligibility

Minimum age: 21 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Established diagnosis of PBC by serological (positive antimitochondrial antibodies)

and/or histological evidence (diagnostic liver biopsy)

- Previous treatment with UDCA 13-15 mg/kg/day for at least 1 year

- Persistent elevation of serum alkaline phosphatase ≥ 2 times the upper limit of

normal on two separate measurements

- Female patients of childbearing age should have a pregnancy test done within -days of

the beginning of this trial, and should agree to be on adequate contraception throughout the study period

- Signed informed consent after careful review of the information and study details by

one of the investigators Exclusion Criteria

- Hypersensitivity to fenofibrate

- Prisoners and institutionalized subjects

- Pregnant or nursing women

- Anticipated need for liver transplantation in one year (estimated one year survival <

80%) as determined by the Mayo risk score. The Mayo risk score takes into account the patient's age, serum bilirubin, albumin and prothrombin time, as well as presence or absence of peripheral edema.

- Recipients of liver transplantation

- Recurrent variceal hemorrhage, uncontrolled encephalopathy or refractory ascites

- Co-existing liver diseases, such as primary sclerosing cholangitis, acute or chronic

hepatitis, alcoholic liver disease, choledocholithiasis, autoimmune hepatitis, cholangiocarcinoma

- Acute or chronic renal failure

- Known history of cholecystitis with intact gallbladder

- Current use of statins, as the concomitant use of fibrates and statins would increase

the risk of toxicity

Locations and Contacts

University of Florida, Gainesville, Florida 32610, United States

Mayo Clinic, Rochester, Minnesota 55905, United States

Additional Information

Related publications:

Levy C, Peter J, Keach J, Petz J, Lindor KD, Cabrera R, et al. Fenofibrate improves liver biochemistries in primary biliary cirrhosis. Hepatology. 2009;50(4 (suppl)):995A.

Starting date: August 2007
Last updated: December 2, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017